文献速递消化系统肿瘤支持与姑息治疗

老年I-III期结直肠癌患者新发心血管疾病风险

New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2018-01-16

高血压与化疗交互增加CVD风险,糖尿病与化疗交互增加CHF风险。

要点

  • 老年结直肠癌患者10年新发CVD和CHF累积发生率显著高于无癌对照(57.4% vs 22%;54.5% vs 18%)。
  • 诊断后2年内,卡培他滨单药较氟尿嘧啶单药增加CHF风险(HR 3.6;95%CI 12.76-4.38)。

核心结论

  • 老年结直肠癌患者新发心血管疾病和充血性心力衰竭风险显著增加。
  • 糖尿病和高血压与化疗交互作用增加心血管疾病风险。

研究设计与样本

  • 基于SEER-Medicare数据库的回顾性队列研究,纳入2000年1月1日至2011年12月31日间年龄>65岁的I-III期结直肠癌患者72,408例,并与匹配的无癌Medicare患者72,408例比较。
  • 中位诊断年龄78岁(范围66-106岁),中位随访时间8年。

主要发现

  • 诊断后2年内,卡培他滨单药较氟尿嘧啶单药增加CHF风险(HR 3.6;95%CI 12.76-4.38)。
  • 氟尿嘧啶单药较卡培他滨单药在诊断后<2年(HR 0.63;95%CI 0.53-0.75)和>2年(HR 0.72;95%CI 0.62-0.84)增加CVD风险。

临床怎么用

  • 对老年结直肠癌患者,尤其合并高血压或糖尿病者,应关注化疗期间及之后的心血管疾病和心力衰竭风险。
  • 使用卡培他滨或氟尿嘧啶时需考虑不同心血管毒性谱,个体化选择化疗方案。
  • 建议对曾暴露于化疗的患者进行结构化心血管监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose We sought to determine the long-term risk of cardiovascular disease (CVD)-stroke and myocardial infarction-and congestive heart failure (CHF) in older patients with colorectal cancer, as well as to understand the roles that preexisting comorbidities and cancer therapy play in increasing this risk. Patients and Methods We evaluated individuals from the SEER-Medicare database with incident stage I to III colorectal cancer at age older than 65 years between January 1, 2000, and December 31, 2011 (n = 72,408) and compared these patients with a matched cohort of Medicare patients without cancer (n = 72,408). Results Median age at diagnosis of colorectal cancer was 78 years (range, 66 years to 106 years), and median follow-up was 8 years since diagnosis. The 10-year cumulative incidence of new-onset CVD and CHF were 57.4% and 54.5% compared with 22% and 18% for control, respectively ( P < .001). The interaction between hypertension and chemotherapy was significant ( P < .001) for CVD, and that between diabetes and chemotherapy was significant ( P < .001) for CHF. Within the first 2 years since diagnosis, exposure to capecitabine alone increased CHF hazard (hazard ratio [HR], 3.6; 95% CI, 12.76 to 4.38) compared with exposure to fluorouracil alone. Conversely, patients who were treated with fluorouracil alone had a higher CVD hazard at < 2 years and > 2 years since diagnosis compared with patients who received capecitabine alone (< 2 years HR, 0.63; 95% CI, 0.53 to 0.75; > 2 years HR, 0.72; 95% CI, 0.62 to 0.84). Conclusion Older patients with colorectal cancer are at increased risk of developing CVD and CHF. Diabetes and hypertension interact with chemotherapy to increase the risk of cardiovascular morbidity. Future studies should assess the potential for personalized therapeutic options for those with preexisting morbidities and for structured monitoring for patients with a history of exposure to chemotherapy regimens, as well as explore the management of preexisting comorbidities to address long-term cardiovascular morbidity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kenzik KM, Balentine C, Richman J, et al. New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer. J Clin Oncol. 2018. PMID: 29337636. doi:10.1200/JCO.2017.74.9739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。